🇺🇸 FDA
Patent

US 7576065

Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein

granted A61KA61K38/185A61K38/30

Quick answer

US patent 7576065 (Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Aug 18 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K38/185, A61K38/30, A61K48/00